Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 5/2016

Open Access 01-05-2016 | Original Article

Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma

Authors: Weijing Zhang, Chunhao Niu, Weiling He, Teng Hou, Xiaoying Sun, Liqun Xu, Yanna Zhang

Published in: Tumor Biology | Issue 5/2016

Login to get access

Abstract

Centrosomal protein 55 (CEP55) is a cell cycle regulator implicated in development of certain cancers. However, characteristics of CEP55 expression and its clinical/prognostic significance are unclear in human epithelial ovarian carcinoma (EOC). Therefore, we investigated the expression and clinicopathological significance of CEP55 in patients with EOC and its role in regulating invasion and metastasis of ovarian cell lines. CEP55 mRNA and protein expression levels were detected by quantitative real-time PCR (qRT-PCR), Western blotting, and immunohistochemistry (IHC). Potential associations of CEP55 expression scores with clinical parameters and patient survival were evaluated. CEP55 function was investigated further using RNA interference, wound healing assay, transwell assay, immunofluorescence analysis, qRT-PCR, and Western blotting. CEP55 was significantly upregulated in ovarian cancer cell lines and lesions compared with normal cells and adjacent noncancerous ovarian tissues. In the 213 EOC samples, CEP55 protein levels were positively correlated with clinical stage (P < 0.001), lymph node metastasis (P < 0.001), intraperitoneal metastasis (P < 0.001), tumor recurrence (P < 0.001), differentiation grade (P < 0.001), residual tumor size (P < 0.001), ascites see tumor cells (P = 0.020), and serum CA153 level (P < 0.001). Moreover, patients with aberrant CEP55 protein expression showed tendencies to receive neoadjuvant chemotherapy (P < 0.001) and cytoreductive surgery (P = 0.020). By contrast, no significant correlation was detected between the protein levels and patient age, histological type, or serum CA125, CA199, CA724, NSE, CEA, and β-HCG levels. Patients with high CEP55 protein expression had shorter overall survival and disease-free survival compared with those with low CEP55 expression. Multivariate analysis implicated CEP55 as an independent prognostic indicator for EOC patients. Additionally, downregulation of CEP55 in ovarian cancer cells remarkably inhibited cellular motility and invasion. Aberrant CEP55 expression may predict unfavorable clinical outcomes in EOC patients and play an important role in regulating invasion in ovarian cancer cells. Thus, CEP55 may serve as a prognostic marker and therapeutic target for EOC.
Literature
1.
2.
Rauh-Hain JA, Krivak TC, del Carmen MG, Olawaiye AB. Ovarian cancer screening and early detection in the general population. Rev Obstet Gynecol. 2011;4(1):15–21.PubMedPubMedCentral
3.
Liu T, Gao H, Chen X, Lou G, Gu L, Yang M, et al. TNFAIP8 as a predictor of metastasis and a novel prognostic biomarker in patients with epithelial ovarian cancer. Br J Cancer. 2013;109(6):1685–92.CrossRefPubMedPubMedCentral
4.
Lynch HT, Casey MJ, Lynch J, White TE, Godwin AK. Genetics and ovarian carcinoma. Semin Oncol. 1998;25:265–80.PubMed
5.
Kyriakopoulou LG, Yousef GM, Scorilas A, Katsaros D, Massobrio M, Fracchioli S, et al. Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer. Clin Biochem. 2003;36(2):135–43.CrossRefPubMed
6.
Park K, Chung YJ, So H, Kim K, Park J, Oh M, et al. AGR2, a mucinous ovarian cancer marker, promotes cell proliferation and migration. Exp Mol Med. 2011;43(2):91–100.CrossRefPubMedPubMedCentral
7.
Papanastasiou AD, Pampalakis G, Katsaros D, Sotiropoulou G. Netrin-1 overexpression is predictive of ovarian malignancies. Oncotarget. 2011;2(5):363–7.CrossRefPubMedPubMedCentral
8.
Wang TH, Chao A, Tsai CL, Chang CL, Chen SH, Lee YS, et al. Stress-induced phosphoprotein 1 as a secreted biomarker for human ovarian cancer promotes cancer cell proliferation. Mol Cell Proteomics. 2010;9(9):1873–84.CrossRefPubMedPubMedCentral
9.
10.
Martinez-Garay I, Rustom A, Gerdes HH, Kutsche K. The novel centrosomal associated protein CEP55 is present in the spindle midzone and the midbody. Genomics. 2006;87(2):243–53.CrossRefPubMed
11.
Zhao WM, Seki A, Fang G. Cep55, a microtubule-bundling protein, associates with centralspindlin to control the midbody integrity and cell abscission during cytokinesis. Mol Biol Cell. 2006;17(9):3881–96.CrossRefPubMedPubMedCentral
12.
Carlton JG, Martin-Serrano J. Parallels between cytokinesis and retroviral budding: a role for the ESCRT machinery. Science. 2007;316(5833):1908–12.CrossRefPubMed
13.
Suzuki H, Kawasaki M, Inuzuka T, Okumura M, Kakiuchi T, Shibata H, et al. Structural basis for Ca2 + -dependent formation of ALG-2/Alix peptide complex: Ca2+/EF3-driven arginine switch mechanism. Structure. 2008;16(10):1562–73.CrossRefPubMed
14.
Chen CH, Lu PJ, Chen YC, Fu SL, Wu KJ, Tsou AP, et al. FLJ10540-elicited cell transformation is through the activation of PI3-kinase/AKT pathway. Oncogene. 2007;26(29):4272–83.CrossRefPubMed
15.
Martin KJ, Patrick DR, Bissell MJ, Fournier MV. Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets. PLoS One. 2008;3(8), e2994.CrossRefPubMedPubMedCentral
16.
Gemenetzidis E, Bose A, Riaz AM, Chaplin T, Young BD, Ali M, et al. FOXM1 upregulation is an early event in human squamous cell carcinoma and it is enhanced by nicotine during malignant transformation. PLoS One. 2009;4(3), e4849.CrossRefPubMedPubMedCentral
17.
Chen CH, Chien CY, Huang CC, Hwang CF, Chuang HC, Fang FM, et al. Expression of FLJ10540 is correlated with aggressiveness of oral cavity squamous cell carcinoma by stimulating cell migration and invasion through increased FOXM1 and MMP-2 activity. Oncogene. 2009;28(30):2723–37.CrossRefPubMed
18.
Chen CH, Lai JM, Chou TY, Chen CY, Su LJ, Lee YC, et al. VEGFA upregulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K/AKT pathway. PLoS One. 2009;4(4), e5052.CrossRefPubMedPubMedCentral
19.
Lai JM, Huang CY, Chen CH. Using siRNA to uncover novel oncogenic signaling pathways. Methods Mol Biol. 2010;623:231–42.CrossRefPubMed
20.
Sakai M, Shimokawa T, Kobayashi T, Matsushima S, Yamada Y, Nakamura Y, et al. Elevated expression of C10orf3 (chromosome 10 open reading frame 3) is involved in the growth of human colon tumor. Oncogene. 2006;25(3):480–6.PubMed
21.
Inoda S, Morita R, Hirohashi Y, Torigoe T, Asanuma H, Nakazawa E, et al. The feasibility of Cep55/c10orf3 derived peptide vaccine therapy for colorectal carcinoma. Exp Mol Pathol. 2011;90(1):55–60.CrossRefPubMed
22.
Shiraishi T, Terada N, Zeng Y, Suyama T, Luo J, Trock B, et al. Cancer/testis antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy. J Transl Med. 2011;9:153.CrossRefPubMedPubMedCentral
23.
Chen CH, Shiu LY, Su LJ, Huang CY, Huang SC, Huang CC, et al. FLJ10540 is associated with tumor progression in nasopharyngeal carcinomas and contributes to nasopharyngeal cell proliferation, and metastasis via osteopontin/CD44 pathway. J Transl Med. 2012;10:93.CrossRefPubMedPubMedCentral
24.
Hwang CF, Shiu LY, Su LJ, Yin Y-F, Wang WS, Huang SC, et al. Oncogenic fibulin-5 promotes nasopharyngeal carcinoma cell metastasis through the FLJ10540/AKT pathway and correlates with poor prognosis. PLoS One. 2013;8(12), e84218.CrossRefPubMedPubMedCentral
25.
Tao J, Zhi X, Tian Y, Li Z, Zhu Y, Wang W, et al. CEP55 contributes to human gastric carcinoma by regulating cell proliferation. Tumour Biol. 2014;35(5):4389–99.CrossRefPubMed
26.
Singh PK, Srivastava AK, Rath SK, Dalela D, Goel MM, Bhatt ML. Expression and clinical significance of centrosomal protein 55(CEP55) in human urinary bladder transitional cell carcinoma. Immunobiology. 2015;220(1):103–8.CrossRefPubMed
27.
Ataseven B, Grimm C, Harter P, Prader S, Traut A, Heitz F, et al. Prognostic value of lymph node ratio in patients with advanced epithelial ovarian cancer. Gynecol Oncol. 2014;135(3):435–40.CrossRefPubMed
28.
Ye Y, Yin M, Huang B, Wang Y, Li X, Lou G. CLIC1 a novel biomarker of intraperitoneal metastasis in serous epithelial ovarian cancer. Tumour Biol. 2015;36(6):4175–9.CrossRefPubMed
29.
Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9:265–73.CrossRefPubMed
30.
Morgan Jr RJ, Alvarez RD, Armstrong DK, Burger RA, Chen LM, Copeland L, et al. National comprehensive cancer networks. Ovarian cancer, version 2.2013. J Natl Compr Cancer Netw. 2013;11(10):1199–209.
31.
Kang S. Neoadjuvant chemotherapy for ovarian cancer: do we have enough evidence? Lancet. 2015;386(9990):223–4.CrossRefPubMed
32.
Baruah U, Barmon D, Kataki AC, Deka P, Hazarika M, Saikia BJ. Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a survival study. Indian J Med Paediatr Oncol. 2015;36(1):38–42.CrossRefPubMedPubMedCentral
33.
Chang SJ, Bristow RE, Chi DS, Cliby WA. Role of aggressive surgical cytoreduction in advanced ovarian cancer. J Gynecol Oncol. 2015. Review.
34.
Dedrick RL, Myers CE, Bungay PM, DeVita Jr VT. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62:1–11.PubMed
35.
Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2011;11, CD005340.
36.
Halkia E, Spiliotis J. The role of cytoreductive surgery and HIPEC in epithelial ovarian cancer. J BUON. 2015;20 Suppl 1:S12–28.PubMed
37.
Bakrin N, Bereder JM, Decullier E, Classe JM, Msika S, Lorimier G, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol. 2013;39(12):1435–43.CrossRefPubMed
Metadata
Title
Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma
Authors
Weijing Zhang
Chunhao Niu
Weiling He
Teng Hou
Xiaoying Sun
Liqun Xu
Yanna Zhang
Publication date
01-05-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4419-6

Other articles of this Issue 5/2016

Tumor Biology 5/2016 Go to the issue

Original Article

Irradiation induces glioblastoma cell senescence and senescence-associated secretory phenotype

Review

ANRIL: a pivotal tumor suppressor long non-coding RNA in human cancers

Original Article

Correlation of IL-27 genetic polymorphisms with the risk and survival of cervical cancer in a Chinese Han population

Original Article

PRSS1 mutations and the proteinase/antiproteinase imbalance in the pathogenesis of pancreatic cancer

Original Article

MiR-145 suppresses cell proliferation and motility by inhibiting ROCK1 in hepatocellular carcinoma

Original Article

miR-615-5p prevents proliferation and migration through negatively regulating serine hydromethyltransferase 2 (SHMT2) in hepatocellular carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits